AN OPEN LETTER

Por Jones, J. R.
Publicado em 1917

Compression screw migration with the sliding hip screw.

Por Hudson, I, Jones, J R
Publicado em 1992

Acute traumatic haemarthrosis of the knee: expectant treatment or arthroscopy?

Por Jones, J. R., Allum, R. L.
Publicado em 1989

Does it matter who requests necropsies? Prospective study of effect of clinical audit on rate of requests.

Por Kamal, I. S., Forsyth, D. R., Jones, J. R.
Publicado em 1997

Infrequent Manifestations of Kabuki Syndrome in a Patient with Novel MLL2 Mutation

Por Zarate, Y.A., Zhan, H., Jones, J.R.
Publicado em 2012

Laboratory compliance with syphilis reporting laws: the New York City experience 1972-77.

Por Felman, Y M, Corsaro, M C, Jones, J R
Publicado em 1980

Current UK opinion on thromboprophylaxis in orthopaedic surgery: its use in routine total hip and knee arthroplasty.

Por Unwin, A. J., Jones, J. R., Harries, W. J.
Publicado em 1995

Computer-Aided Chemistry at Surrey — the way ahead

Por Buist, G. J., Howlin, B., Jones, J. R., Povey, D. C.
Publicado em 1989

Elevated blood lead in California adults, 1987: results of a statewide surveillance program based on laboratory reports.

Por Maizlish, N, Rudolph, L, Sutton, P, Jones, J R, Kizer, K W
Publicado em 1990

Clinical cholera caused by enterotoxigenic Escherichia coli.

Por Finkelstein, R A, Vasil, M L, Jones, J R, Anderson, R A, Barnard, T
Publicado em 1976

3H-n.m.r. studies of multiple conformations and dynamic processes in complexes of folate and methotrexate with Lactobacillus casei dihydrofolate reductase.

Por Curtis, N, Moore, S, Birdsall, B, Bloxsidge, J, Gibson, C L, Jones, J R, Feeney, J
Publicado em 1994

Cobalt-containing bioactive glasses reduce human mesenchymal stem cell chondrogenic differentiation despite HIF-1α stabilisation

Por Littmann, E., Autefage, H., Solanki, A.K., Kallepitis, C., Jones, J.R., Alini, M., Peroglio, M., Stevens, M.M.
Publicado no J Eur Ceram Soc (2018)

Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?

Por Pawlyn, C, Fowkes, L, Otero, S, Jones, J R, Boyd, K D, Davies, F E, Morgan, G J, Collins, D J, Sharma, B, Riddell, A, Kaiser, M F, Messiou, C
Publicado no Leukemia (2016)

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

Por Pawlyn, C, Bright, M D, Buros, A F, Stein, C K, Walters, Z, Aronson, L I, Mirabella, F, Jones, J R, Kaiser, M F, Walker, B A, Jackson, G H, Clarke, P A, Bergsagel, P L, Workman, P, Chesi, M, Morgan, G J, Davies, F E
Publicado no Blood Cancer J (2017)

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial

Por Jones, J R, Cairns, D A, Gregory, W M, Collett, C, Pawlyn, C, Sigsworth, R, Striha, A, Henderson, R, Kaiser, M F, Jenner, M, Cook, G, Russell, N H, Williams, C, Pratt, G, Kishore, B, Lindsay, J, Drayson, M T, Davies, F E, Boyd, K D, Owen, R G, Jackson, G H, Morgan, G J
Publicado no Blood Cancer J (2016)

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients

Por Shah, V, Sherborne, A L, Walker, B A, Johnson, D C, Boyle, E M, Ellis, S, Begum, D B, Proszek, P Z, Jones, J R, Pawlyn, C, Savola, S, Jenner, M W, Drayson, M T, Owen, R G, Houlston, R S, Cairns, D A, Gregory, W M, Cook, G, Davies, F E, Jackson, G H, Morgan, G J, Kaiser, M F
Publicado no Leukemia (2018)